{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:34:00Z","timestamp":1781109240878,"version":"3.54.1"},"reference-count":0,"publisher":"National Academy of Sciences","issue":"22","content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[1991,11,15]]},"abstract":"<jats:p>CP-96,345 [(2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl) methyl]-1-azabicyclo[2.2.2]octan-3-amine) antagonism of substance P-stimulated salivation was investigated in pentobarbital-anesthetized rats. Administered either intraperitoneally or orally, CP-96,345 produced dose-dependent inhibition of the sialogogic response elicited by substance P, with a median effective dose of 12-24 mumol\/kg (5-10 mg\/kg) of body weight, but had no effect on acetylcholine-stimulated salivation. CP-96,345 produced concentration-dependent inhibition of [3H]substance P binding to rat submaxillary gland membranes, with a median effective concentration of 34 +\/- 3.6 nM. These biological activities were confined to CP-96,345 in that the 2R,3R enantiomer (CP-96,344) was without effect.<\/jats:p>","DOI":"10.1073\/pnas.88.22.10042","type":"journal-article","created":{"date-parts":[[2006,5,31]],"date-time":"2006-05-31T07:50:38Z","timestamp":1149061838000},"page":"10042-10044","update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":25,"title":["Effect of CP-96,345, a nonpeptide substance P receptor antagonist, on salivation in rats."],"prefix":"10.1073","volume":"88","author":[{"given":"R M","family":"Snider","sequence":"first","affiliation":[{"name":"Department of Exploratory Medicinal Chemistry, Pfizer, Inc., Groton, CT 06340."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K P","family":"Longo","sequence":"additional","affiliation":[{"name":"Department of Exploratory Medicinal Chemistry, Pfizer, Inc., Groton, CT 06340."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S E","family":"Drozda","sequence":"additional","affiliation":[{"name":"Department of Exploratory Medicinal Chemistry, Pfizer, Inc., Groton, CT 06340."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"3rd","given":"J A","family":"Lowe","sequence":"additional","affiliation":[{"name":"Department of Exploratory Medicinal Chemistry, Pfizer, Inc., Groton, CT 06340."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S E","family":"Leeman","sequence":"additional","affiliation":[{"name":"Department of Exploratory Medicinal Chemistry, Pfizer, Inc., Groton, CT 06340."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[1991,11,15]]},"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.88.22.10042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T13:19:17Z","timestamp":1649855957000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.88.22.10042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,11,15]]},"references-count":0,"journal-issue":{"issue":"22","published-print":{"date-parts":[[1991,11,15]]}},"alternative-id":["10.1073\/pnas.88.22.10042"],"URL":"https:\/\/doi.org\/10.1073\/pnas.88.22.10042","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991,11,15]]},"assertion":[{"value":"1991-11-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}